LNF2007

LNF2007 is a small molecule dual inhibitor of histone deacetylase 3 (HDAC3) and bromodomain-containing protein 4 (BRD4) currently under investigation for the treatment of advanced solid tumors. Developed by Shandong New Time Pharmaceutical, a subsidiary of Lunan Pharmaceutical Group, the compound belongs to a class of 4,5-dihydro-benzo[g]indazole-based hydroxamic acids designed to target epigenetic mechanisms involved in oncogenesis. By simultaneously inhibiting HDAC3 and BRD4, LNF2007 aims to disrupt gene expression patterns that drive tumor proliferation and survival. It is being evaluated in Phase I clinical trials as an intravenous monotherapy to determine its safety, tolerability, and preliminary efficacy in patients with advanced malignancies.